Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes

被引:0
|
作者
Blanco, FJ
Guitian, R
Moreno, J
de Toro, FJ
Galdo, F
机构
[1] Juan Canalejo Hosp, Lab Cartilage Res, Rheumatol Unit, A Coruna, Spain
[2] Juan Canalejo Hosp, Tissue Bank, A Coruna, Spain
[3] Fdn Juan Canalejo, A Coruna, Spain
[4] Boehringer Ingelheim KG, Madrid, Spain
关键词
cartilage; cyclooxygenase; osteoarthritis; chondrocytes; meloxicam;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective, To study the effect of steroidal and nonsteroidal antiinflammatory drugs (NSAID) on cyclooxygenase (COX-1 and COX-2) activity in human articular chondrocytes. Methods. Chondrocytes were isolated from articular cartilage of donors with no articular disease. Unstimulated and interleukin 1 (IL-1) stimulated chondrocytes were used as models to study the effects of drugs on COX-1 and COX-2. Cells were incubated with vehicle or drugs; supernatants were removed and the level of prostaglandin E-2 (PGE(2)) in each sample was determined by enzyme immunoassay. IC50 were calculated from the reduction in PGE(2) content by different concentrations of the test substance by linear regression analysis. Results, COX-1 mRNA was detected in unstimulated cells, but stimulation with IL-1 for up 12 h did not modify the levels of COX-1 mRNA. In contrast, COX-2 mRNA was not detectable in unstimulated cells, but it was induced by IL-1. Dexamethasone inhibited COX-2 mRNA expression induced by IL-1, COX-2, protein levels correlated with mRNA expression. Dexamethasone was the strongest drug inhibitor of COX-2 (IC50 = 0.0073 mu M). However, it did not inhibit COX-1 activity. Among all NSAID tested, meloxicam and aspirin were the least potent inhibitors of COX-1 (IC50 = 36.6 mu M and 3.57 mu M, respectively). Indomethacin and diclofenac were the most patent inhibitors of COX-1 (IC50 = 0.063 mu M and 0.611 mu M, respectively) and COX-2 isoforms (IC50 = 0.48 mu M and IC50 = 0.63 mu M, respectively). Meloxicam was a more potent inhibitor of COX-2 (IC50 = 4.7 mu M) than aspirin (IC50 = 29.3 mu M) and similar to piroxicam (IC50 = 4.4 mu M). Among all drugs tested dexamethasone showed the greatest selectivity for COX-2 and meloxicam was the NSAID with the best COX-2/COX-1 ratio (r = 0.12). Aspirin and piroxicam were about 8 times more active against COX-1 than COX-2, indomethacin was 7 times more active, and diclofenac was an equipotent inhibitor of COX-1 and COX-2. Conclusion. We found that COX-1 and COX-2 isoforms are expressed in human chondrocytes at rest and in IL-1 stimulated cells, respectively. Antiinflammatory drugs have different capacities to inhibit COX enzyme in human articular chondrocytes.
引用
收藏
页码:1366 / 1373
页数:8
相关论文
共 50 条
  • [31] Development of more selective NSAIDS: Cox-1 and Cox-2
    Barragry, T
    IRISH VETERINARY JOURNAL, 1996, 49 (09) : 553 - &
  • [32] Distribution of COX-1 and COX-2 in normal and inflamed tissues
    Seibert, K
    Zhang, Y
    Leahy, K
    Hauser, S
    Masferrer, J
    Isakson, P
    EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY 2, PTS A AND B, 1997, 400 : 167 - 170
  • [33] The role of COX-1 and COX-2 isozymes in experimental cholera
    Gessell-Lee, DL
    Peterson, JW
    GASTROENTEROLOGY, 2001, 120 (05) : A323 - A323
  • [34] Does the COX-1/COX-2 concept still hold?
    Hawkey, C
    UPDATE GASTROENTEROLOGY 2004: NEW DEVELOPMENTS IN THE MANAGEMENT OF BENIGN GASTROINTESTINAL DISORDERS, 2004, : 87 - 89
  • [35] COX-2, but not COX-1, is involved in mechanotransduction in bone cells
    Bakker, AD
    Burger, EH
    Semeins, CM
    Klein-Nulend, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S215 - S215
  • [36] The pyrrole moiety as a template for COX-1/COX-2 inhibitors
    Dannhardt, G
    Kiefer, W
    Krämer, G
    Maehrlein, S
    Nowe, U
    Fiebich, B
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2000, 35 (05) : 499 - 510
  • [37] Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques
    McGeer, PL
    McGeer, EG
    Yasojima, K
    EXPERIMENTAL GERONTOLOGY, 2002, 37 (07) : 925 - 929
  • [38] Structure of COX-1 and COX-2 enzymes and their interaction with inhibitors
    Bakhle, YS
    DRUGS OF TODAY, 1999, 35 (4-5): : 237 - 250
  • [39] COX-1 and COX-2 tissue expression: Implications and predictions
    Crofford, LJ
    JOURNAL OF RHEUMATOLOGY, 1997, 24 : 15 - 19
  • [40] Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracaena loureiri
    Likhitwitayawuid, K
    Sawasdee, K
    Kirtikara, K
    PLANTA MEDICA, 2002, 68 (09) : 841 - 843